“The Phase 1 clinical trial is designed to evaluate the safety, reactogenicity, and immunogenicity of ARCT-2304 as a potential vaccine to protect against the highly pathogenic H5N1 avian influenza.” ...
While there has not been another large coastal wildlife outbreak of H5N1 since, researchers estimated that about 10-14% of the Caspian tern population in the Pacific flyway have been lost to H5N1 ...
Results that may be inaccessible to you are currently showing.